HCW Biologics Inc.
HCWB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001828673
In the last 90 days, HCW Biologics Inc. insiders filed 3 open-market purchases and 0 sales; 12 institutions reported holding it in 13F filings for Q2 2026, worth $515.7K in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $100.0K in total
- 3
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −3 vs. previous quarter
- 12
- 13F valueReported value at the end of Q2 2026
- $515.7K
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding HCWB, Q2 2026
No superinvestor reported holding HCWB at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by HCW Biologics Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 31, 2026 (view filing)4:10 PM ET | Jul 29 | 2 days | Wong Hing CChief Executive Officer | PPurchase | +23.2K | $2.59 | +$60.0K | +22.6%125.8K after | |
| Jul 31, 2026 (view filing)4:06 PM ET | Jul 29 | 2 days | Flowers LeeSVP of Business Development | PPurchase | +7.74K | $2.59 | +$20.0K | +810.1%8.69K after | |
| Jul 31, 2026 (view filing)4:02 PM ET | Jul 29 | 2 days | Garrett Scott TDirector | PPurchase | +7.74K | $2.59 | +$20.0K | +22.8%41.6K after | |
| May 27, 2026 (view filing) | May 22 | 5 days | Wong Hing CChief Executive Officer | PPurchase | +113.9K | $1.41 | +$160.6K | +22.7%615.8K after | |
| May 27, 2026 (view filing) | May 22 | 5 days | Wong Hing CChief Executive Officer | PPurchase | +113.9K | $0.00 | $0 | –118.1K after | Derivative |
| May 27, 2026 (view filing) | May 22 | 5 days | Garrett Scott TDirector | PPurchase | +177.9K | $1.41 | +$250.9K | +697.7%203.4K after | |
| May 27, 2026 (view filing) | May 22 | 5 days | Garrett Scott TDirector | PPurchase | +177.9K | $0.00 | $0 | –180.6K after | Derivative |
| May 27, 2026 (view filing) | May 22 | 5 days | Byam RebeccaChief Financial Officer | PPurchase | +14.2K | $1.41 | +$20.1K | +33.1%57.2K after | |
| May 27, 2026 (view filing) | May 22 | 5 days | Byam RebeccaChief Financial Officer | PPurchase | +14.2K | $0.00 | $0 | –18.5K after | Derivative |
| May 20, 2025 (view filing) | May 16 | 4 days | Wong Hing CChief Executive Officer | PPurchase | +8.05K | $7.45 | +$60.0K | +1.6%501.9K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in HCW Biologics Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Jane Street Group, LLC | 52,138 | $260.2K | 0.00% | +38,004+268.9% | Added |
| Citadel Advisors LLC | 19,942 | $99.5K | 0.00% | −6,141−23.5% | Reduced |
| HRT Financial LP | 13,583 | $67.0K | 0.00% | −252,810−94.9% | Reduced |
| Vanguard Fiduciary Trust Co | 6,510 | $32.5K | 0.00% | +4,607+242.1% | Added |
| Tower Research Capital LLC (TRC) | 4,117 | $20.5K | 0.00% | −10,722−72.3% | Reduced |
| Connective Capital Management, LLC | 3,338 | $16.7K | 0.01% | +3,338 | New |
| Vanguard Capital Management LLC | 2,003 | $9.99K | 0.00% | −10,020−83.3% | Reduced |
| Golden State Wealth Management, LLC | 1,667 | $8.32K | 0.00% | −8,333−83.3% | Reduced |
| Barclays PLC | 191 | $953 | 0.00% | +191 | New |
| Advisor Group Holdings, Inc. | 4 | $20 | 0.00% | −22−84.6% | Reduced |